PCI Biotech Holding ASA (0JGL) Q1 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to PCI Biotech's Q1 2023 presentation. My name is Ronny Skogedal, and with me today are Anders Haugset and Morten Lur. First of all, let's take a look at our important notice and disclaimer. This is the agenda for today. In the end, we will have a Q&A session. You can send questions via the web console. You can start with that now. First, some highlights from QN. Bioprocess for the use of Fimanac for the production of gene therapy. We applied for the first patent in the fall of 2022. In QN 2023, we used it to generate data that supplemented the initial application. What does your external world say about the customer value of our application? We get positive feedback, and we also get feedback that potential future customers may want to test our application, as long as we can show data that proves our idea. That is what we will focus on in the future, generating data that can trigger external testing of Fimanac for bioproduction. Regarding dermatology, where we want to demonstrate the delivery of nucleic acids to wounds with the help of Fimanac. The first step in this early phase project is planned in a wound model. The run-in phase of these experiments is ongoing, and we expect to be able to report this by next quarter's presentation. Positive results from such a study will of course be used to generate cooperation. Then, Fimavac, where we want to use the technology in connection with intratumoral immunotherapy, and this can make it possible for new treatment combinations. The first patent was also applied in Q1, and this is also a project that is supported by the Research Council by a PhD candidate for three years in the future, now from Q1. Corporate, we have now, as previously communicated, a financial runway towards the end of 2024. This...